Studies indicated that TME-accumulated TAMs can be targeted through anti-CSF1R with short-term treatment protocol to inhibit GBM progression via inhibiting chemokines such as CXCL7 (human IL8 variant) in animal models [39,86,131]. Here, CSF1R is linked to glioblastoma.